Evaluation of the post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 zygomycetes using two different media

被引:11
作者
Vitale, RG
Meis, JFGM
Mouton, JW
Verweij, PE
机构
[1] Univ Med Ctr Nijmegen, Dept Med Microbiol, NL-6500 HB Nijmegen, Netherlands
[2] Univ Nijmegen, Ctr Infect Dis, Nijmegen, Netherlands
[3] Canisius Wilhelmina Hosp, Dept Med Microbiol & Infect Dis, Nijmegen, Netherlands
关键词
PAFE; zygomycetes; amphotericin B; nystatin;
D O I
10.1093/jac/dkg285
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The post-antifungal effect (PAFE) of amphotericin B and nystatin against 30 clinical zygomycetes was evaluated using two different media. PAFE is a suppression of fungal growth after limited drug exposure. The MICs of both drugs were determined using NCCLS M38-P guidelines. A spectrophotometric method was used to determine PAFE in vitro. Spores were exposed to amphotericin B and nystatin in RPMI-1640 or AM3 at concentrations of 4 x and 1 x MIC for 4 h for Absidia sp. and at 1 x and 0.5 x MIC for 1 h for the other strains. Drugs were eliminated by washing. Exposed and control spores were cultured in microtitre wells and incubated for 48 h. PAFE was calculated as T - C (Deltat) between the control and the exposure fungi. The first increase in optical density (OD0) was used to calculate PAFE and was considered significant when the value of the lower 95%CI of the exposed strain was greater than the upper 95%CI of the control. MIC ranges in RPMI-1640 were: 0.06-4 mg/L for amphotericin B and 0.5-8 mg/L for nystatin; MIC ranges in AM3 were: 0.06-2 mg/L for amphotericin B and 0.5-4 mg/L for nystatin. Killing was not observed at the concentration and exposure time used. In RPMI-1640, for amphotericin B the rank order for PAFE was Absidia corymbifera (5.6 h) > Rhizopus oryzae (5.2 h) > Mucor spp. (3.5 h) > Rhizopus microsporus (3 h), and for nystatin the rank order was Mucor spp. (5.8 h) > R. oryzae (3.3 h) > A. corymbifera (2.9 h) > R. microsporus (1.7 h). PAFE was not induced in Rhizomucor spp. PAFE was dependent on drug concentration.
引用
收藏
页码:65 / 70
页数:6
相关论文
共 23 条
[1]   In vivo pharmacodynamics of antifungal drugs in treatment of candidiasis [J].
Andes, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (04) :1179-1186
[2]   Pharmacodynamics of amphotericin B in a neutropenic-mouse disseminated-candidiasis model [J].
Andes, D ;
Stamsted, T ;
Conklin, R .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) :922-926
[3]   TISSUE CONCENTRATIONS AND BIOACTIVITY OF AMPHOTERICIN-B IN CANCER-PATIENTS TREATED WITH AMPHOTERICIN-B-DEOXYCHOLATE [J].
COLLETTE, N ;
VANDERAUWERA, P ;
LOPEZ, AP ;
HEYMANS, C ;
MEUNIER, F .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1989, 33 (03) :362-368
[4]  
Cormican MG, 1996, J ANTIMICROB CHEMOTH, V38, P561
[5]   In vitro susceptibilities of zygomycetes to combinations of antimicrobial agents [J].
Dannaoui, E ;
Afeltra, J ;
Meis, JFGM ;
Verweij, PE .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (08) :2708-2711
[6]   Overview of the lipid formulations of amphotericin B [J].
Dupont, B .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2002, 49 :31-36
[7]  
Ellepola ANB, 1999, J ORAL PATHOL MED, V28, P112, DOI 10.1111/j.1600-0714.1999.tb02007.x
[8]   Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans [J].
Ernst, EJ ;
Klepser, ME ;
Pfaller, MA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :1108-1111
[9]  
Espinel-Ingroff A, 1998, MED MYCOL, V36, P68
[10]   Compartmental pharmacokinetics and tissue distribution of multilamellar liposomal nystatin in rabbits [J].
Groll, AH ;
Mickiene, D ;
Werner, K ;
Petraitiene, R ;
Petraitis, V ;
Calendario, M ;
Field-Ridley, A ;
Crisp, J ;
Piscitelli, SC ;
Walsh, TJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2000, 44 (04) :950-957